Found: 75
Select item for more details and to access through your institution.
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 655, doi. 10.1007/s40257-024-00859-y
- By:
- Publication type:
- Article
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 669, doi. 10.1007/s40257-024-00855-2
- By:
- Publication type:
- Article
The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 3, p. e291, doi. 10.1111/jdv.19627
- By:
- Publication type:
- Article
A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis.
- Published in:
- Pediatric Dermatology, 2024, v. 41, n. 2, p. 204, doi. 10.1111/pde.15518
- By:
- Publication type:
- Article
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Pediatric Drugs, 2024, v. 26, n. 2, p. 163, doi. 10.1007/s40272-023-00611-9
- By:
- Publication type:
- Article
Dupilumab treatment provides long-term improvement in itch in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii56, doi. 10.1093/bjd/ljad498.058
- By:
- Publication type:
- Article
Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis.
- Published in:
- Pharmaceutical Research, 2023, v. 40, n. 11, p. 2653, doi. 10.1007/s11095-023-03616-8
- By:
- Publication type:
- Article
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 5, p. 787, doi. 10.1007/s40257-023-00791-7
- By:
- Publication type:
- Article
Disseminated Papules and Nodules on the Skin and Oral Mucosa in an Infant.
- Published in:
- Cutis, 2023, v. 112, n. 3, p. 131, doi. 10.12788/cutis.0851
- By:
- Publication type:
- Article
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 1987, doi. 10.1007/s13555-023-00960-w
- By:
- Publication type:
- Article
Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines.
- Published in:
- Pediatric Dermatology, 2023, v. 40, n. 5, p. 789, doi. 10.1111/pde.15327
- By:
- Publication type:
- Article
402 Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.025
- By:
- Publication type:
- Article
437 Treatment-emergent adverse events in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis treated with dupilumab in an open-label extension clinical trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.057
- By:
- Publication type:
- Article
411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.032
- By:
- Publication type:
- Article
410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.031
- By:
- Publication type:
- Article
Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 6, p. 637, doi. 10.1001/jamadermatol.2023.0549
- By:
- Publication type:
- Article
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 5, p. 526, doi. 10.1001/jamadermatol.2023.0391
- By:
- Publication type:
- Article
336 Efficacy of dupilumab in infants and preschoolers with atopic dermatitis up to 1 year.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii24, doi. 10.1093/bjd/ljac140.030
- By:
- Publication type:
- Article
337 Dupilumab treatment is not associated with an increased overall risk of infections in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii25, doi. 10.1093/bjd/ljac140.031
- By:
- Publication type:
- Article
338 Laboratory safety from a 16-week phase 3 study of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii26, doi. 10.1093/bjd/ljac140.032
- By:
- Publication type:
- Article
342 A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii30, doi. 10.1093/bjd/ljac140.036
- By:
- Publication type:
- Article
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 1, p. 67, doi. 10.1007/s40272-022-00553-8
- By:
- Publication type:
- Article
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data.
- Published in:
- Pediatric Dermatology, 2022, v. 39, n. 2, p. 187, doi. 10.1111/pde.14909
- By:
- Publication type:
- Article
The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 5, p. 1318, doi. 10.1002/cpt.2366
- By:
- Publication type:
- Article
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1643, doi. 10.1007/s13555-021-00568-y
- By:
- Publication type:
- Article
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Analysis of over‐the‐counter products marketed to treat molluscum contagiosum.
- Published in:
- Pediatric Dermatology, 2021, v. 38, n. 5, p. 1400, doi. 10.1111/pde.14776
- By:
- Publication type:
- Article
Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
- Published in:
- Pediatric Drugs, 2021, v. 23, n. 5, p. 515, doi. 10.1007/s40272-021-00459-x
- By:
- Publication type:
- Article
A rare case of childhood mucous membrane pemphigoid involving the oral and genital mucosa.
- Published in:
- Pediatric Dermatology, 2021, v. 38, n. 4, p. 904, doi. 10.1111/pde.14627
- By:
- Publication type:
- Article
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
- Published in:
- American Journal of Clinical Dermatology, 2021, v. 22, n. 2, p. 243, doi. 10.1007/s40257-020-00583-3
- By:
- Publication type:
- Article
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
- Published in:
- American Journal of Clinical Dermatology, 2021, v. 22, n. 2, p. 257, doi. 10.1007/s40257-020-00570-8
- By:
- Publication type:
- Article
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
- Published in:
- American Journal of Clinical Dermatology, 2021, v. 22, n. 1, p. 101, doi. 10.1007/s40257-020-00577-1
- By:
- Publication type:
- Article
Effects of variations in access to care for children with atopic dermatitis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus‐based guidance for clinical decision‐making during the COVID‐19 pandemic.
- Published in:
- Pediatric Dermatology, 2020, v. 37, n. 3, p. 424, doi. 10.1111/pde.14202
- By:
- Publication type:
- Article
Frey syndrome‐like developmental dysautonomia in a child with PHACE syndrome.
- Published in:
- Pediatric Dermatology, 2020, v. 37, n. 3, p. 568, doi. 10.1111/pde.14125
- By:
- Publication type:
- Article
A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 1, p. 119, doi. 10.1007/s40257-019-00478-y
- By:
- Publication type:
- Article
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pediatric dermatology workforce in the United States.
- Published in:
- Pediatric Dermatology, 2019, v. 36, n. 1, p. 166, doi. 10.1111/pde.13684
- By:
- Publication type:
- Article
Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis.
- Published in:
- Pediatric Dermatology, 2019, v. 36, n. 1, p. 172, doi. 10.1111/pde.13707
- By:
- Publication type:
- Article
A Systematic Scoping Literature Review of Publications Supporting Treatment Guidelines for Pediatric Atopic Dermatitis in Contrast to Clinical Practice Patterns.
- Published in:
- Dermatology & Therapy, 2018, v. 8, n. 3, p. 349, doi. 10.1007/s13555-018-0243-4
- By:
- Publication type:
- Article
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.
- Published in:
- Pediatric Dermatology, 2018, v. 35, n. 3, p. 303, doi. 10.1111/pde.13452
- By:
- Publication type:
- Article
Pediatric psoriasis: Evolving perspectives.
- Published in:
- Pediatric Dermatology, 2018, v. 35, n. 2, p. 170, doi. 10.1111/pde.13382
- By:
- Publication type:
- Article
Paradoxic eczema in infants after heart transplantation.
- Published in:
- Pediatric Dermatology, 2018, v. 35, n. 1, p. e29, doi. 10.1111/pde.13342
- By:
- Publication type:
- Article
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Characterization of children with recurrent eczema herpeticum and response to treatment with interferon-gamma.
- Published in:
- Pediatric Dermatology, 2017, v. 34, n. 6, p. 686, doi. 10.1111/pde.13301
- By:
- Publication type:
- Article
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Impact of a Pediatric Dermatology Service on Emergency Department Utilization for Children with Dermatitis.
- Published in:
- Pediatric Dermatology, 2016, v. 33, n. 1, p. 69, doi. 10.1111/pde.12688
- By:
- Publication type:
- Article
Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants.
- Published in:
- Pediatric Allergy & Immunology, 2015, v. 26, n. 4, p. 306, doi. 10.1111/pai.12331
- By:
- Publication type:
- Article